Thursday 19 February 2026

The Pharmaletter

Adocia

A clinical-stage biopharma company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity.

Company Overview

Want to Update your Company's Profile?


Latest Adocia News

Impressive Humalog comparison sends Adocia shares skywards
25 July 2025
Adocia walks away empty-handed in latest Lilly IP dispute
23 August 2019
Adocia to present data on ultra-rapid insulin BioChaperone Lispro
27 September 2018
Adocia wins round one in Lilly legal battle
21 August 2018
More Adocia news >


Today's issue

Positive billing but Ocular’s Axpaxli data disappoints investors
Pharmaceutical
Positive billing but Ocular’s Axpaxli data disappoints investors
18 February 2026
Pharmaceutical
Novartis’ remibrutinib closes in on further urticaria indication
18 February 2026
Pharmaceutical
Recordati delivers solid year, with more to come in 2026
18 February 2026
Biotechnology
Unnatural Products strikes up to $1.7B partnership with Novartis
18 February 2026
Biosimilars
Sandoz wins expanded US FDA approval for Enzeevu
18 February 2026
Biotechnology
FDA to initiate review of Moderna seasonal flu vaccine submission
18 February 2026
Biotechnology
Korsana Biosciences emerges with $175 million funding
18 February 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze